Teijin Limited

Teijin Pharma Limited

Kunio Minamizono

Susumu Takeuchi

Yoshiyuki Matsumoto

Minoru Imai

Tomonori Yokoyama

Akinobu Nakanishi

Yoshiyuki Sawai

Hiroshi Takahashi

Gen Unoki

Kosuke Sasaki

Tsuyoshi Mizuno

Akinobu Maruyama

Yuri Sakai

Kyohei Horie

Takuya Yokosaka

Junji Igarashi

Tomohiro Shimada

Masaru Ebisawa

The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. 

Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C-Calkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis. 

4,4-disubstituted piperidine derivatives having CCR3 antagonism

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C-Calkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis. 

Piperidine derivatives having CCR3 antagonism

Growing community of inventors

Tokyo, Japan

Kunio Minamizono